Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Bipolar Disorder
Measuring lithium from a fingertip
The sensor has the potential to enable patients to take the right amount of lithium to alleviate the symptoms of bipolar disorder and depression, the scientists said in a presentation at the American Chemical Society (ACS) fall meeting on Sunday.
August 22, 2022
Castle Biosciences completes $65M AltheaDx acquisition
Under the terms of the definitive agreement, AltheaDx became a subsidiary of Castle Biosciences. At closing, Castle paid $65 million to AltheaDx security holders, which consisted of $32.5 million in cash and $32.5 million in Castle common stock.
April 26, 2022
Low-volume test platform from Baebies wins 'disruptive tech' award at AACC
In the third annual edition of the Disruptive Technology Award competition, Baebies won the award for Finder, a near-patient testing platform featuring a toaster-sized instrument and disposable cartridge. Powered by digital microfluidics technology, Baebies' Finder tests for diseases using low sample volumes with a turnaround time of approximately 15 minutes after sample introduction.
December 14, 2020
New recommendations for CYP2C9 testing | Biomarker emerges in prostate cancer | T2 Biosystems reports data for bacteria panel
Dear LabPulse Member,
May 13, 2019
Failed study leaves CRP test hanging as biomarker in bipolar depression
The results leave the potential role of CRP as a biomarker up in the air. They also highlight the broader challenges in developing biomarkers and personalized treatments in the field of psychiatry.
May 7, 2019
Most Popular
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
Cue Health Q4 revenues decline 24% as firm expands, diversifies POC test menu
Page 1 of 1
